Remdesivir Clinical Trial

The infectious disease division is conducting a randomized controlled trial to evaluate the investigational antiviral agent remdesivir in patients with COVID-19.

Eligibility criteria include: positive COVID-19 test, fever and abnormal chest Xray or CT

Please page 15013 (COVID19) in Smartpage if you have a patient who might be eligible or if you have a question about a patient who is already on the study.

We greatly appreciate your help in making this trial a success! Please see below for FAQ.

What is the investigational drug and what are the side effects?
Remdesivir is an RNA dependent RNA polymerase inhibitor. It is similar to the HIV medicine tenofovir. It is given as a once daily IV infusion. It is generally well-tolerated and has been studied in clinical trials of ebola. Side effects are rare but can include transient elevation of AST and ALT and elevated creatinine.

How does my patient get into the study?
After you call the study pager 15013 or after the investigators identify your patient as eligible, one of the investigators will reach out to your team and meet with the patient to see if they are interested in participating.

How/when does my patient get the study drug?
If your patient is enrolled in the study, the study drug will be ordered by the study team and provided by the investigational pharmacy. The drug will generally be given between 8 am and 5 pm when the study coordinators are on site.

Who is sponsoring the trial?
The sponsor is Gilead Pharmaceuticals, the maker of remdesivir. The investigators have no financial interest in the trial.

What should I do if I think my patient is having side effects of the drug?
If there is a reaction during the infusion which is concerning for an allergy (this has not been seen with this medication), then stop the medication. Otherwise please call the study pager at 15013.

How long is the study drug given?
It is a daily infusion given for 5-10 days.

What do I do if my patient is improved and ready to go home before the course of the study drug has been completed?
Please notify the study team at pager 15013. We will not hold up your patients discharge and they can be discharged before the course of the study drug is completed (that counts as a success!). But please do not stop the study drug without notifying the study team. This will cause us to violate the study protocol and jeopardize Stanford’s ability to complete this or future similar trials.
What should I do if I have more questions?
Please feel free to call the study pager at 15013 or contact one of the investigators:

Aruna Subramanian – asubram2@stanford.edu
Phil Grant – pmgrant@stanford.edu
Shanthi Kappagoda – skappago@stanford.edu